Navitoclax, the orally bioavailable derivative of ABT737, had not obtained FDA approval due to dose-limiting thrombocytopenia noticed in phase I studies, an effect that could be attributed to BCL-XL inhibition [36–38]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.